ANDASUBCUTANEOUSSOLUTION
Approved
Sep 2022
Lifecycle
Post-LOE
Competitive Pressure
30/100
Data completeness
2/8 — Basic
ISOSULFAN BLUE (isosulfan blue) by Fresenius Kabi is 12. First approved in 2022.
Drug data last refreshed 20h ago
Mechanism of Action
12.2 Pharmacodynamics Following subcutaneous administration, isosulfan blue injection 1% binds to serum proteins and is picked up by the lymphatic vessels. Thus, the lymphatic vessels are delineated by the blue dye. 12.3 Pharmacokinetics Up to 10% of the subcutaneously administered dose of…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Company
Fresenius Kabi
Worked on ISOSULFAN BLUE at Fresenius Kabi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.